Deirdre Somers Sells 1,637 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.53, for a total transaction of $17,237.61. Following the completion of the transaction, the director now directly owns 41,675 shares in the company, valued at $438,837.75. This trade represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Enfusion Stock Performance

ENFN opened at $10.97 on Friday. The firm has a market cap of $1.41 billion, a P/E ratio of 274.19, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95. The business has a 50 day moving average price of $10.25 and a 200 day moving average price of $9.26. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.38.

Institutional Trading of Enfusion

A number of institutional investors and hedge funds have recently modified their holdings of ENFN. Geode Capital Management LLC raised its holdings in Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after acquiring an additional 70,367 shares during the period. Wellington Management Group LLP grew its position in shares of Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. Scalar Gauge Management LLC increased its stake in shares of Enfusion by 21.8% in the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares during the period. Renaissance Technologies LLC lifted its position in shares of Enfusion by 167.6% during the 2nd quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock worth $827,000 after purchasing an additional 60,811 shares during the last quarter. Finally, Barclays PLC boosted its stake in Enfusion by 251.4% during the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after purchasing an additional 61,554 shares during the period. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on ENFN. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday. Stifel Nicolaus lifted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.